Janelle R. Anderson, PhD, Managing Partner of CTI Life Sciences Fund, has started a new podcast, Human Proof of Concept, in which she interviews business leaders within the life sciences and venture capital spaces. The goal is to bring light to new medicine and technology.
In the first two episodes, She speaks with Ron Cohen, CEO and founder of Acorda Therapeutics and Chair of BIO. In the interviews, he discusses his career and its challenges/successes, comments on the high drama from 2015 and how it has affected the industry and also discusses the drug pricing conversation that has been especially prevalent lately. He also touches on new trends for biotech coming up.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Other podcasts or publications on a similar subject include Lisa Suennen’s Tech Tonics as well as Bruce Booth’s Blog Life Sci VC.
You can listen to the first two episodes of Human Proof of Concept below – both are about thirty minutes long.
Part 1:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Part 2:
